U.S. Prescription Drugs Market Size, Share, Trends, & Industry Analysis Report By Ailment (Alzheimer’s, Parkinson’s, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder) – Market Forecast, 2025–2034
Description
The U.S. prescription drugs market size is expected to reach USD 67.51 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Prescription Drugs Market Share, Size, Trends, Industry Analysis Report: By Ailment (Alzheimer’s, Parkinson’s, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Prescription drugs are described as physician-authorized medications formulated to treat specific health conditions with safety and efficacy standards, are evolving in response to dynamic industry trends. The growing use of personalized and precision medicine emphasizes the importance of tailoring treatments to individual genetic, biological, and lifestyle factors. This shift is encouraging greater demand for therapies that deliver targeted outcomes while reducing adverse effects, reshaping the way drugs are developed and prescribed. This trend is setting a new benchmark for treatment effectiveness and long-term healthcare value by aligning pharmaceutical innovation with patient-specific needs.
The increasing integration of digital health technologies into the development and delivery of prescription drugs further drives the market growth. Innovations such as digital therapeutics, AI-driven drug discovery, and connected health navigation platforms are transforming the design, testing, and monitoring of therapies in real-world use. These advancements accelerate the drug development lifecycle and also improve patient adherence and engagement, strengthening the overall impact of therapies. Together, these trends highlight the transformation of prescription drugs into a more technology-driven and patient-centric domain, positioning the market for sustained innovation and adaptability.
U.S. Prescription Drugs Market Report Highlights
In terms of ailment, the alzheimer's segment generated USD 2.31 billion in revenue in 2024, driven by growing rates of age-related cognitive decline and rising demand for long-term treatment solutions in the U.S.
A few global key market players include AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb; Eli Lilly and Company; Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; Moderna, Inc.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc.
Polaris Market Research has segmented the market report on the basis of ailment:
By Ailment Outlook (Revenue, USD Billion, 2020–2034)
Alzheimer’s
Parkinson’s
Migraine
Chronic pain
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Post-Operative Pain
Fibromyalgia
Bone Fracture
Muscle Pain
Acute Appendicitis
Sleep disorders
Insomnia
Hypersomnia
Sleep Apnea
Sleep Breathing Disorder
Circadian Rhythm Disorders
Parasomnia
Sleep Movement Disorders
Major Depressive Disorder
Prescription drugs are described as physician-authorized medications formulated to treat specific health conditions with safety and efficacy standards, are evolving in response to dynamic industry trends. The growing use of personalized and precision medicine emphasizes the importance of tailoring treatments to individual genetic, biological, and lifestyle factors. This shift is encouraging greater demand for therapies that deliver targeted outcomes while reducing adverse effects, reshaping the way drugs are developed and prescribed. This trend is setting a new benchmark for treatment effectiveness and long-term healthcare value by aligning pharmaceutical innovation with patient-specific needs.
The increasing integration of digital health technologies into the development and delivery of prescription drugs further drives the market growth. Innovations such as digital therapeutics, AI-driven drug discovery, and connected health navigation platforms are transforming the design, testing, and monitoring of therapies in real-world use. These advancements accelerate the drug development lifecycle and also improve patient adherence and engagement, strengthening the overall impact of therapies. Together, these trends highlight the transformation of prescription drugs into a more technology-driven and patient-centric domain, positioning the market for sustained innovation and adaptability.
U.S. Prescription Drugs Market Report Highlights
In terms of ailment, the alzheimer's segment generated USD 2.31 billion in revenue in 2024, driven by growing rates of age-related cognitive decline and rising demand for long-term treatment solutions in the U.S.
A few global key market players include AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb; Eli Lilly and Company; Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; Moderna, Inc.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc.
Polaris Market Research has segmented the market report on the basis of ailment:
By Ailment Outlook (Revenue, USD Billion, 2020–2034)
Alzheimer’s
Parkinson’s
Migraine
Chronic pain
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Post-Operative Pain
Fibromyalgia
Bone Fracture
Muscle Pain
Acute Appendicitis
Sleep disorders
Insomnia
Hypersomnia
Sleep Apnea
Sleep Breathing Disorder
Circadian Rhythm Disorders
Parasomnia
Sleep Movement Disorders
Major Depressive Disorder
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. U.S. Prescription Drugs Market Insights
- 4.1. U.S. Prescription Drugs Market – Market Snapshot
- 4.2. U.S. Prescription Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Technological Innovation in Biologics, Gene/Cell Therapy
- 4.2.1.2. Aging Population and Chronic Disease Prevalence
- 4.2.2. High Cost and Limited Reimbursement
- 4.2.2.1. Political and Public Pressure for Price Controls & Reform
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. U.S. Prescription Drugs Market Trends
- 4.6. Value Chain Analysis
- 5. U.S. Prescription Drugs Market, by Ailment
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
- 5.3. Alzheimer’s
- 5.3.1. U.S. Prescription Drugs Market, by Alzheimer’s, 2020-2034 (USD Billion)
- 5.4. Parkinson’s
- 5.4.1. U.S. Prescription Drugs Market, by Parkinson’s, 2020-2034 (USD Billion)
- 5.5. Migraine
- 5.5.1. U.S. Prescription Drugs Market, by Migraine, 2020-2034 (USD Billion)
- 5.6. Chronic pain
- 5.6.1. U.S. Prescription Drugs Market, by Chronic Pain, 2020-2034 (USD Billion)
- 5.6.2. Arthritic Pain
- 5.6.2.1. U.S. Prescription Drugs Market, by Arthritic Pain, 2020-2034 (USD Billion)
- 5.6.3. Neuropathic Pain
- 5.6.3.1. U.S. Prescription Drugs Market, by Neuropathic Pain, 2020-2034 (USD Billion)
- 5.6.4. Cancer Pain
- 5.6.4.1. U.S. Prescription Drugs Market, by Cancer Pain, 2020-2034 (USD Billion)
- 5.6.5. Chronic Back Pain
- 5.6.5.1. U.S. Prescription Drugs Market, by Chronic Back Pain, 2020-2034 (USD Billion)
- 5.6.6. Post-Operative Pain
- 5.6.6.1. U.S. Prescription Drugs Market, by Post-Operative Pain, 2020-2034 (USD Billion)
- 5.6.7. Fibromyalgia
- 5.6.7.1. U.S. Prescription Drugs Market, by Fibromyalgia, 2020-2034 (USD Billion)
- 5.6.8. Bone Fracture
- 5.6.8.1. U.S. Prescription Drugs Market, by Bone Fracture, 2020-2034 (USD Billion)
- 5.6.9. Muscle Pain
- 5.6.9.1. U.S. Prescription Drugs Market, by Muscle Pain, 2020-2034 (USD Billion)
- 5.6.10. Acute Appendicitis
- 5.6.10.1. U.S. Prescription Drugs Market, by Acute Appendicitis, 2020-2034 (USD Billion)
- 5.7. Sleep Disorders
- 5.7.1. U.S. Prescription Drugs Market, by Sleep Disorders Products, 2020-2034 (USD Billion)
- 5.7.2. Insomnia
- 5.7.2.1. U.S. Prescription Drugs Market, by Insomnia, 2020-2034 (USD Billion)
- 5.7.3. Hypersomnia
- 5.7.3.1. U.S. Prescription Drugs Market, by Hypersomnia, 2020-2034 (USD Billion)
- 5.7.4. Sleep Apnea
- 5.7.4.1. U.S. Prescription Drugs Market, by Sleep Apnea, 2020-2034 (USD Billion)
- 5.7.5. Sleep Breathing Disorder
- 5.7.5.1. U.S. Prescription Drugs Market, by Sleep Breathing Disorder, 2020-2034 (USD Billion)
- 5.7.6. Circadian Rhythm Disorders
- 5.7.6.1. U.S. Prescription Drugs Market, by Circadian Rhythm Disorders, 2020-2034 (USD Billion)
- 5.7.7. Parasomnia
- 5.7.7.1. U.S. Prescription Drugs Market, by Parasomnia, 2020-2034 (USD Billion)
- 5.7.8. Sleep Movement Disorders
- 5.7.8.1. U.S. Prescription Drugs Market, by Sleep Movement Disorders, 2020-2034 (USD Billion)
- 5.8. Major Depressive Disorders
- 5.8.1. U.S. Prescription Drugs Market, by Major Depressive Disorders, 2020-2034 (USD Billion)
- 6. Competitive Landscape
- 6.1. Expansion and Acquisition Analysis
- 6.1.1. Expansion
- 6.1.2. Acquisitions
- 6.2. Partnerships/Collaborations/Agreements/Exhibitions
- 7. Company Profiles
- 7.1. AbbVie, Inc.
- 7.1.1. Company Overview
- 7.1.2. Financial Performance
- 7.1.3. Product Benchmarking
- 7.1.4. Recent Development
- 7.2. Amgen, Inc.
- 7.2.1. Company Overview
- 7.2.2. Financial Performance
- 7.2.3. Product Benchmarking
- 7.2.4. Recent Development
- 7.3. Bristol Myers Squibb
- 7.3.1. Company Overview
- 7.3.2. Financial Performance
- 7.3.3. Product Benchmarking
- 7.3.4. Recent Development
- 7.4. Eli Lilly and Company
- 7.4.1. Company Overview
- 7.4.2. Financial Performance
- 7.4.3. Product Benchmarking
- 7.4.4. Recent Development
- 7.5. Gilead Sciences, Inc.
- 7.5.1. Company Overview
- 7.5.2. Financial Performance
- 7.5.3. Product Benchmarking
- 7.5.4. Recent Development
- 7.6. Johnson & Johnson (Janssen Pharmaceuticals)
- 7.6.1. Company Overview
- 7.6.2. Financial Performance
- 7.6.3. Product Benchmarking
- 7.6.4. Recent Development
- 7.7. Merck & Co., Inc.
- 7.7.1. Company Overview
- 7.7.2. Financial Performance
- 7.7.3. Product Benchmarking
- 7.7.4. Recent Development
- 7.8. Moderna, Inc.
- 7.8.1. Company Overview
- 7.8.2. Financial Performance
- 7.8.3. Product Benchmarking
- 7.8.4. Recent Development
- 7.9. Pfizer, Inc.
- 7.9.1. Company Overview
- 7.9.2. Financial Performance
- 7.9.3. Product Benchmarking
- 7.9.4. Recent Development
- 7.10. Regeneron Pharmaceuticals, Inc.
- 7.10.1. Company Overview
- 7.10.2. Financial Performance
- 7.10.3. Product Benchmarking
- 7.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.